The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Phase II study update of TL-895 in patients with myelofibrosis with severe thrombocytopenia
Michael Loschi, MD, PhD, University Hospital of Nice, Cote d’Azur University, Nice, France, discusses an ongoing Phase II study investigating the efficacy and safety of TL-895 monotherapy, a first-in-class covalent BTK inhibitor, in patients with myelofibrosis (MF) with severe thrombocytopenia (NCT04640532). Dr Loschi shares some data from the first 11 patients including survival, spleen volume reduction and improvement in patient platelet counts. Dr Loschi also comments on the encouraging safety data and tolerability of the treatment. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honorarium: Novartis, Gilead, Pfizer, Sobi, BMS, Abbvie, Janssen, Astrazeneca, Alexion, GSK, Incyte, Morphosys, Telios, Kartos
